Compare Asian CDMOs across India, China, Japan, South Korea, and Southeast Asia. Filter by manufacturing type, regulatory approvals, and capacity for API synthesis, biologics, and drug products.
707 companies listed
Asia is the fastest-growing CDMO market, led by India (API synthesis powerhouse), China (increasingly sophisticated biologics and small molecule capabilities), South Korea (biosimilar manufacturing leader), and Japan (high-quality specialty manufacturing). Together, Asian CDMOs produce an estimated 60-80% of the world's active pharmaceutical ingredients.
India dominates small molecule API manufacturing. The country has over 3,000 pharmaceutical manufacturing facilities, many FDA-inspected, producing APIs for global generics markets. Indian CDMOs offer 30-50% cost advantages over Western alternatives for chemical synthesis. However, quality varies significantly -- due diligence on facility inspection history and quality systems is essential.
South Korea and Japan represent the premium end of Asian CDMO manufacturing. Samsung Biologics and Celltrion in South Korea have built world-class biologics facilities (up to 360,000L combined capacity). Japanese CDMOs (AGC Biologics' Chiba facility, FUJIFILM Diosynth) offer exceptional quality systems and specialized capabilities. China's WuXi Biologics and WuXi AppTec, though affected by BIOSECURE Act uncertainty, remain major global players.
Every country below has its own page with a ranked CDMO list, a country-zoomed facilities map, and the local regulatory picture. Counts are live manufacturing-site totals.
India
Kemwell Biopharma is one of India's largest biologics CDMOs, providing integrated drug substance and drug product development and manufacturing services from a single site in Bangalore. Established with technological support from a leading German biopharmaceutical company, Kemwell serves global pharma and biotech organizations with capabilities spanning monoclonal antibodies, complex fusion proteins, recombinant proteins, and bispecific antibodies. The company has received U.S. FDA approval for commercial drug product manufacturing and operates hybrid biomanufacturing with both stainless steel and single-use bioreactor systems.
China
KinOmega Biopharm Inc. is a leading Chinese manufacturer of Omega-3 fish oil EPA/DHA, producing both pharmaceutical-grade (API) and nutraceutical-grade products. They hold 9 DMFs, 4 GMP approvals (US FDA, Korean FDA, Japan PMDA), and CEP/COS certification for pharmaceutical-grade purity. Their FDA-registered facility (FEI 3009754809) has been inspected with 0 observations. KinOmega uses proprietary 3-times molecular distillation purification with 11-stage SPD technology. They also operate a softgel production line (4 million capsules/day). This is an API and ingredient manufacturer, not a contract drug product CDMO. Their products meet Ph. Eur. and USP standards.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.